-
Je něco špatně v tomto záznamu ?
EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology
P. Brennecke, D. Rasina, O. Aubi, K. Herzog, J. Landskron, B. Cautain, F. Vicente, J. Quintana, J. Mestres, B. Stechmann, B. Ellinger, J. Brea, JL. Kolanowski, R. Pilarski, M. Orzaez, A. Pineda-Lucena, L. Laraia, F. Nami, P. Zielenkiewicz, K....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- kooperační chování * MeSH
- lidé MeSH
- objevování léků metody MeSH
- preklinické hodnocení léčiv MeSH
- rychlé screeningové testy MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Compound screening in biological assays and subsequent optimization of hits is indispensable for the development of new molecular research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chemical biology from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN's compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3 H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-molecule-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacological chaperones for inborn errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-molecule screening, the plethora of assay designs, and the close connection between screening and medicinal chemistry within EU-OPENSCREEN.
Central Office Berlin EU OPENSCREEN Germany
Centre for Molecular Medicine Norway Nordic EMBL Partnership University of Oslo Oslo Norway
Department of Biomedicine University of Bergen Bergen Norway
Department of Chemistry CZ OPENSCREEN Masaryk University Brno Czech Republic
Department of Experimental and Health Sciences Universitat Pompeu Fabra Barcelona Catalunya Spain
Drug Discovery Unit Health Research Institute Hospital La Fe Valencia Spain
EU OPENSCREEN Leibniz Research Institute for Molecular Pharmacology Berlin Germany
Faculty of Biochemistry and Molecular Medicine Biocenter Oulu University of Oulu Oulu Finland
Fraunhofer Institute for Molecular Biology and Applied Ecology IME Screening Port Hamburg Germany
Fundación MEDINA Health Sciences Technology Park Granada Spain
Institute of Molecular Genetics of the ASCR CZ OPENSCREEN Prague Czech Republic
Organic Synthesis Methodology Group Latvian Institute of Organic Synthesis Riga Latvia
Screening Platform Principe Felipe Research Center Valencia Spain
Screening Unit Leibniz Research Institute for Molecular Pharmacology Berlin Germany
The Arctic University of Norway University of Tromsø Marbio Tromsø Norway
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022881
- 003
- CZ-PrNML
- 005
- 20201214124927.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/2472555218816276 $2 doi
- 035 __
- $a (PubMed)30616481
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brennecke, Philip $u 1 EU-OPENSCREEN, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 245 10
- $a EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology / $c P. Brennecke, D. Rasina, O. Aubi, K. Herzog, J. Landskron, B. Cautain, F. Vicente, J. Quintana, J. Mestres, B. Stechmann, B. Ellinger, J. Brea, JL. Kolanowski, R. Pilarski, M. Orzaez, A. Pineda-Lucena, L. Laraia, F. Nami, P. Zielenkiewicz, K. Paruch, E. Hansen, JP. von Kries, M. Neuenschwander, E. Specker, P. Bartunek, S. Simova, Z. Leśnikowski, S. Krauss, L. Lehtiö, U. Bilitewski, M. Brönstrup, K. Taskén, A. Jirgensons, H. Lickert, MH. Clausen, JH. Andersen, MJ. Vicent, O. Genilloud, A. Martinez, M. Nazaré, W. Fecke, P. Gribbon,
- 520 9_
- $a Compound screening in biological assays and subsequent optimization of hits is indispensable for the development of new molecular research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chemical biology from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN's compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3 H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-molecule-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacological chaperones for inborn errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-molecule screening, the plethora of assay designs, and the close connection between screening and medicinal chemistry within EU-OPENSCREEN.
- 650 12
- $a kooperační chování $7 D003299
- 650 _2
- $a objevování léků $x metody $7 D055808
- 650 _2
- $a preklinické hodnocení léčiv $7 D004353
- 650 _2
- $a rychlé screeningové testy $7 D057166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rasina, Dace $u 2 Organic Synthesis Methodology Group, Latvian Institute of Organic Synthesis, Riga, Latvia.
- 700 1_
- $a Aubi, Oscar $u 3 Department of Biomedicine, University of Bergen, Bergen, Norway.
- 700 1_
- $a Herzog, Katja $u 1 EU-OPENSCREEN, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 700 1_
- $a Landskron, Johannes $u 4 Centre for Molecular Medicine Norway-Nordic EMBL Partnership, University of Oslo, Oslo, Norway.
- 700 1_
- $a Cautain, Bastien $u 5 Fundación MEDINA, Health Sciences Technology Park, Granada, Spain.
- 700 1_
- $a Vicente, Francisca $u 5 Fundación MEDINA, Health Sciences Technology Park, Granada, Spain.
- 700 1_
- $a Quintana, Jordi $u 6 Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalunya, Spain.
- 700 1_
- $a Mestres, Jordi $u 6 Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalunya, Spain. 7 IMIM Hospital del Mar Medical Research Institute, Research Program on Biomedical Informatics (GRIB), Barcelona, Spain.
- 700 1_
- $a Stechmann, Bahne $u 1 EU-OPENSCREEN, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 700 1_
- $a Ellinger, Bernhard $u 8 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Screening Port, Hamburg, Germany.
- 700 1_
- $a Brea, Jose $u 9 Institute for Research in Molecular Medicine and Chronic Diseases-BioFarma Research Group, University of Santiago de Compostela, Santiago de Compostela, Spain.
- 700 1_
- $a Kolanowski, Jacek L $u 10 Department of Molecular Probes and Prodrugs, Institute of Bioorganic Chemistry-Polish Academy of Sciences, Poznan, Poland.
- 700 1_
- $a Pilarski, Radosław $u 10 Department of Molecular Probes and Prodrugs, Institute of Bioorganic Chemistry-Polish Academy of Sciences, Poznan, Poland.
- 700 1_
- $a Orzaez, Mar $u 11 Screening Platform, Principe Felipe Research Center, Valencia, Spain.
- 700 1_
- $a Pineda-Lucena, Antonio $u 12 Drug Discovery Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
- 700 1_
- $a Laraia, Luca $u 13 Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Lyngby, Denmark. 14 Technical University of Denmark, DK-OPENSCREEN, Lyngby, Denmark.
- 700 1_
- $a Nami, Faranak $u 13 Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Lyngby, Denmark. 14 Technical University of Denmark, DK-OPENSCREEN, Lyngby, Denmark.
- 700 1_
- $a Zielenkiewicz, Piotr $u 15 Department of Bioinformatics, Institute of Biochemistry and Biophysics-Polish Academy of Sciences, Warsaw, Poland.
- 700 1_
- $a Paruch, Kamil $u 16 Department of Chemistry-CZ-OPENSCREEN, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Hansen, Espen $u 17 The Arctic University of Norway, University of Tromsø, Marbio, Tromsø, Norway.
- 700 1_
- $a von Kries, Jens P $u 18 Screening Unit, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 700 1_
- $a Neuenschwander, Martin $u 18 Screening Unit, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 700 1_
- $a Specker, Edgar $u 19 Medicinal Chemistry Research Group, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 700 1_
- $a Bartunek, Petr $u 20 Institute of Molecular Genetics of the ASCR, CZ-OPENSCREEN, Prague, Czech Republic.
- 700 1_
- $a Simova, Sarka $u 20 Institute of Molecular Genetics of the ASCR, CZ-OPENSCREEN, Prague, Czech Republic.
- 700 1_
- $a Leśnikowski, Zbigniew $u 21 Laboratory of Molecular Virology and Biological Chemistry, Institute of Medical Biology-Polish Academy of Sciences, Łódź, Poland.
- 700 1_
- $a Krauss, Stefan $u 22 Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. 23 Hybrid Technology Hub-Centre of Excellence-Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
- 700 1_
- $a Lehtiö, Lari $u 24 Faculty of Biochemistry and Molecular Medicine-Biocenter Oulu, University of Oulu, Oulu, Finland.
- 700 1_
- $a Bilitewski, Ursula $u 25 Working Group Compound Profiling and Screening, Helmholtz Centre for Infection Research, Brunswick, Germany.
- 700 1_
- $a Brönstrup, Mark $u 26 Department of Chemical Biology, Helmholtz Centre for Infection Research, Brunswick, Germany. 27 German Center for Infection Research (DZIF), partner site Hannover-Brunswick, Brunswick, Germany.
- 700 1_
- $a Taskén, Kjetil $u 4 Centre for Molecular Medicine Norway-Nordic EMBL Partnership, University of Oslo, Oslo, Norway. 28 Department of Cancer Immunology-Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 29 K.G. Jebsen Centre for Cancer Immunotherapy-Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 30 K.G. Jebsen Centre for B Cell Malignancies-Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- 700 1_
- $a Jirgensons, Aigars $u 2 Organic Synthesis Methodology Group, Latvian Institute of Organic Synthesis, Riga, Latvia.
- 700 1_
- $a Lickert, Heiko $u 31 Institute of Diabetes and Regeneration Research, Helmholtz Centre Munich German Research Center for Environmental Health, Neuherberg, Germany.
- 700 1_
- $a Clausen, Mads H $u 13 Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Lyngby, Denmark. 14 Technical University of Denmark, DK-OPENSCREEN, Lyngby, Denmark.
- 700 1_
- $a Andersen, Jeanette H $u 17 The Arctic University of Norway, University of Tromsø, Marbio, Tromsø, Norway.
- 700 1_
- $a Vicent, Maria J $u 11 Screening Platform, Principe Felipe Research Center, Valencia, Spain.
- 700 1_
- $a Genilloud, Olga $u 5 Fundación MEDINA, Health Sciences Technology Park, Granada, Spain.
- 700 1_
- $a Martinez, Aurora $u 3 Department of Biomedicine, University of Bergen, Bergen, Norway.
- 700 1_
- $a Nazaré, Marc $u 19 Medicinal Chemistry Research Group, Leibniz Research Institute for Molecular Pharmacology, Berlin, Germany.
- 700 1_
- $a Fecke, Wolfgang $u 32 Central Office, Berlin, EU-OPENSCREEN, Germany.
- 700 1_
- $a Gribbon, Philip $u 8 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Screening Port, Hamburg, Germany.
- 773 0_
- $w MED00205671 $t SLAS discovery : advancing life sciences R & D $x 2472-5560 $g Roč. 24, č. 3 (2019), s. 398-413
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30616481 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214124927 $b ABA008
- 999 __
- $a ok $b bmc $g 1595200 $s 1113557
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 3 $d 398-413 $e 20190107 $i 2472-5560 $m SLAS discovery $n SLAS Discov $x MED00205671
- LZP __
- $a Pubmed-20201125
